Vascular dementia, unspecified severity, with mood disturbance
Methodology & AI Transparency ⓘ
Vascular dementia, unspecified severity, with mood disturbance Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Vascular dementia, unspecified severity, with mood disturbance uses ICD-10 F01.53 across Memory & Cognition specialty care.
- 3 Typical cash cost range: Clinicians assessing Vascular dementia, unspecified severity, with mood disturbance focus on cholinergic basal forebrain in Vascular dementia, unspecified severity, with mood disturbance (F01.53: depletion) and targeted history.
- 4 Top reported side effects / signs: Key Memory & Cognition biomarkers for Vascular dementia, unspecified severity, with mood disturbance (F01.53): Homocysteine & Vitamin in Vascular dementia, unspecified severity, with mood disturbance (F01.53: B12) & TSH & Fasting in Vascular dementia, unspecified severity, with mood disturbance (F01.53: ApoB / HbA1c) (Optimal cardiometabolic neuroprotection (F01.53)).
Ask our AI Specialists anything about Vascular dementia, unspecified severity, with mood disturbance
What Is Vascular dementia, unspecified severity, with mood disturbance?
Recognized across U.S. clinical coding as F01.53 (Memory & Cognition), Vascular dementia, unspecified severity, with mood disturbance is evaluated via reversible metabolic/medication/sleep-apnea workup [Vascular dementia, unspecified severity, with mood disturbance F01.53] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Vascular dementia, unspecified severity, with mood disturbance (F01.53) alters memory & cognition homeostasis through cholinergic basal forebrain in Vascular dementia, unspecified severity, with mood disturbance (F01.53: depletion); clinical remission targets TSH & Fasting in Vascular dementia, unspecified severity, with mood disturbance (F01.53: ApoB / HbA1c) within Optimal cardiometabolic neuroprotection (F01.53).
Common Symptoms & Clinical Signs
- • Presentation of Vascular dementia, unspecified severity, with mood disturbance (F01.53): slowed processing speed in Vascular dementia, unspecified severity, with mood disturbance (F01.53: compared with prior)
- • Secondary Vascular dementia, unspecified severity, with mood disturbance clinical sign: short-term recall difficulty in Vascular dementia, unspecified severity, with mood disturbance (F01.53: for recent conversations,)
- • Symptom flares in Vascular dementia, unspecified severity, with mood disturbance correlating with Homocysteine & Vitamin in Vascular dementia, unspecified severity, with mood disturbance (F01.53: B12) deviation outside Homocysteine < 9 umol/L; B12 > 500 pg/mL (F01.53)
- • Functional memory & cognition impact requiring reversible metabolic/medication/sleep-apnea workup [Vascular dementia, unspecified severity, with mood disturbance F01.53] evaluation (F01.53)
Vascular dementia, unspecified severity, with mood disturbance Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F01.53 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Vascular dementia, unspecified severity, with mood disturbance (F01.53: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (F01.53) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Vascular dementia, unspecified severity, with mood disturbance (F01.53: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (F01.53) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Vascular dementia, unspecified severity, with mood disturbance (F01.53: Score) | >= 26 / 30 (F01.53) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vascular dementia, unspecified severity, with mood disturbance
Treatment selection for Vascular dementia, unspecified severity, with mood disturbance depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vascular dementia, unspecified severity, with mood disturbance)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and: What a 21,135-Participant Study Found GLP1RA therapy when compared to placebo reduced all-cause mortality in high heart and blood vessel risk patients with type 2 diabetes. Current diabetes reviews • 2018-01-15 • Meta-Analysis | N = 21,135 | 99/100 | PMID 28413990 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
Vascular dementia, unspecified severity, with mood disturbance Patient Community & “People Like Me” Threads
Filter Vascular dementia, unspecified severity, with mood disturbance community threads and patient logs by age, biological sex, dosage, and treatment duration.